sighi-medication-manual-table-of-contents

SIGHI Medication Manual - Table of Contents

SIGHI Medication Manual: Medical treatment in histaminosis

Information about mast cell activation diseases (mastocytosis, MCAS), for persons concerned and healthcare professionals

03.01.2019

www.mastzellaktivierung.info

Table of Contents:

• 1 Preliminary remarks
• 1.1 Disclaimer, disclosure duty
• 1.2 Abbreviations. Definitions
• 1.3 Fundamentals of MCAD medical treatment
• 1.4 Tolerability of medicines
• 1.4.1 Incompatible active ingredients
• 1.4.2 Incompatible excipients
• 2 Overview: Who needs which medication when?
• 2.1 Medical treatment for systemic mast cell activation disorders (MCAD)
• 2.1.1 Therapeutic strategy for MCAD
• 2.1.2 Basic therapy
• 2.1.3 Symptomatic supplemental treatment
• 2.1.3.1 Pain
• 2.1.3.2 Disorders of the digestive tract
• 2.1.3.3 Miscellaneous symptoms and disorders
• 2.2 Medication for histamine intolerance (DAO associated histamine degradation disorder)22
• 2.2.1 Basic therapy
• 2.2.2 Symptomatic supplemental treatment
• 2.2.3 Additional measures in severe cases
• 2.3 Medication for intestinal dysbiosis, small intestinal bacterial overgrowth
• 3 Medicinal products (Medications)
• 3.1 Antihistamines (histamine receptor antagonists)
• 3.1.1 H1 antihistamines (H1 receptor antagonists)
• 3.1.1.1 Bilastine
• 3.1.1.2 Cetirizine
• 3.1.1.3 Clemastine (Tavegyl®)
• 3.1.1.4 Desloratadine (= descarboethoxyloratadine, DCL)
• 3.1.1.5 Dimenhydrinate
• 3.1.1.6 Dimetindene (dimethindene) (CH: Feniallerg®, D: Fenistil®)
• 3.1.1.7 Diphenhydramine
• 3.1.1.8 Fexofenadine
• 3.1.1.9 Hydroxizine
• 3.1.1.10 Ketotifen (Zaditen®)
• 3.1.1.11 Levocetirizine, levocetirizine dihydrochloride (Xyzal®)
• 3.1.1.12 Loratadine
• 3.1.1.13 Rupatadine
• 3.1.2 H2-antihistamines (H2-receptor antagonists), ranitidine
• 3.1.3 Other antihistaminergic agents
• 3.2 Mast cell stabilizers
• 3.2.1 Cromoglicinic acid, sodium cromoglicate
• 3.2.1.1 Nalcrom®
• 3.2.2 Ketotifen (Zaditen®)
• 3.3 Prostaglandin synthesis inhibitors, non-steroidal antiinflammatory drugs (NSAIDs) △
• 3.3.1 Ibuprofen △
• 3.3.2 Dexibuprofen △
• 3.3.3 Acetylsalicylic acid (ASS) △
• 3.3.4 Etoricoxib (Arcoxia®)
• 3.3.5 Celecoxib (Celebrex®)
• 3.4 Leukotriene inhibitors
• 3.5 Analgesics
• 3.5.1 Paracetamol (Acetaminophen)
• 3.6 Proton pump inhibitors
• 3.7 Cannabinoids, cannabinoid receptor agonists
• 3.7.1 Hemp, cannabis
• 3.7.2 Tetrahydrocannabinol (THC)
• 3.7.3 Cannabidiol (CBD)
• 3.7.4 Palmitoylethanolamide (PEA)
• 3.8 Opiates, opioids △
• 3.9 Psychiatric medications
• 3.9.1 Antidepressants
• 3.9.2 Neuroleptics, antipsychotics
• 3.9.3 Benzodiazepines
• 3.10 Immunosuppressants, immunomodulators
• 3.10.1 Glucocorticoids
• 3.10.1.1 Natural Glucocorticoids
• 3.10.1.2 Synthetic glucocorticoids
• 3.10.2 Azathioprine
• 3.10.3 Methotrexate
• 3.11 Anti-IgE monoclonal antibodies
• 3.11.1 Omalizumab
• 3.12 Tyrosine kinase inhibitors, inhibitors of other kinases
• 3.12.1 Imatinib
• 3.12.2 Masitinib
• 3.12.3 Midostaurin
• 3.12.4 Crenolanib
• 3.12.5 Sunitinib
• 3.12.6 Nilotinib
• 3.12.7 Dasatinib
• 3.13 Cytoreductive therapy, chemotherapy, cytostatics
• 3.13.1 Interferon-α
• 3.13.2 Cladribine
• 3.13.3 Hydroxyurea
• 3.13.4 Thalidomide
• 3.14 Stem cell transplantation
• 4 Medical devices
• 4.1 Clinoptilolite, zeolite
• 5 Foods for special medical purposes
• 5.1 Diamine oxidase (DAO)
• 5.1.1 DAOSIN®
• 5.2 Probiotics
• 5.2.1 Lactopia Probio Histamed®
• 6 Nutritional supplements
• 6.1 Vitamin C
• 6.2 Vitamin D3 (cholecalciferol)
• 6.3 Zinc
• 6.4 Natural mast cell stabilizers
• 6.4.1 Chondroitin sulfate, chondroitin
• 6.4.2 Flavonoids △
• 6.4.2.1 Quercetin △
• 6.4.3 Curcumin
• 6.4.4 Stilbene derivatives (stilbenoids)
• 6.4.5 Ellagic acid
• 6.5 Selenium
• 7 Preparations for an emergency
• 7.1 Anaphylaxis, anaphylactic shock
• 7.1.1 Definitions
• 7.1.2 Gradation of severity
• 7.2 Interventions in anaphylactic / anaphylactoid shock
• 7.3 Emergency kit
• 7.3.1 Content of the emergency kit
• 7.3.2 Use of the emergency kit
• 7.3.2.1 At ONSET of reaction
• 7.3.2.2 In case of a SEVERE reaction
• 7.4 Medical alert card
• 7.5 Living will
• 8 Premedication before medical interventions
• 8.1 Rationale for the need for premedication
• 8.2 Anesthesia / surgery / invasive examinations
• 8.2.1 General considerations
• 8.2.2 Prior to an operation (= preoperative)
• 8.2.3 During an operation (= intraoperative)
• 8.2.4 After an operation (= postoperative)
• 8.2.5 Compatibility of frequently used active ingredients in medical interventions
• 8.3 local anaesthesia, regional anaesthesia
• 8.4 Examinations containing contrast medium (X-ray, CT, MRI)
• 8.5 Dental medicine and MCAD / Histaminosis
• 8.5.1 Premedication in dentistry
• 8.5.2 General information for the dentist
• 8.5.3 Tolerable products for local anesthesia in dentistry
• 8.5.3.1 Switzerland
• 8.5.3.2 Germany
• 8.5.3.3 Austria
• 8.6 Vaccinations
• 8.6.1 Compatibility of vaccinations in MCAD
• 8.6.2 To vaccinate: yes or no?
• 8.6.3 Self-centered versus societal considerations
• 8.6.4 Compulsory vaccination
• 8.6.5 Precautions for vaccinations
• 9 Medicinal treatment in the event of disease
• 9.1 Flu-like infection, common cold, sore throat, bacterial infection
• 9.1.1 Antipyretics, cold medication
• 9.1.2 Sore throat
• 9.1.3 Nutritional supplementation
• 9.1.4 Bacterial secondary infections (frontal and maxillary sinusitis)
• 9.1.5 Inappropriate for infections
• 9.2 Antibiotics
• 9.3 Allergies
• 9.3.1 Respiratory allergies
• 9.4 Swallowing disorders, dysphagia
• 10 Medicinal treatment in special situations
• 10.1 Pregnancy and lactation
• 10.1.1 Medicinal treatment for pregnant and lactating women
• 10.1.1.1 Recommended substances
• 10.1.1.2 Less well suited
• 10.1.1.3 Imperatively to be avoided
• 10.1.2 Psychiatric medications during pregnancy
• 11 References
• 12 Annex
• Annex: incompatible active substances